Download PDF
Thromb Haemost 2012; 108(06): 1246-1248
DOI: 10.1160/TH12-08-0556
Letters to the Editor
Schattauer GmbH

Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term

Chiara Giannarelli   *
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Giovanni Cimmino   *
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Borja Ibanez
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
2   CNIC, Madrid, Spain
,
Giulia Chiesa
3   Dipartimento di Scienze Farmacologiche e Biomoleculari, Universitàdegli Studi di Milano, Milan, Italy
,
Jaime Garcia-Prieto
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Carlos G. Santos-Gallego
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Matilde Alique-Aguilar
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Valentin Fuster
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
2   CNIC, Madrid, Spain
,
Cesare Sirtori
3   Dipartimento di Scienze Farmacologiche e Biomoleculari, Universitàdegli Studi di Milano, Milan, Italy
,
Juan J. Badimon
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
› Author Affiliations Financial support:This study was supported in part by Pfizer, manufacturer of recombinant apoA-I Milano (ETC-216).
Further Information

Publication History

Received: 06 August 2012

Accepted after major revision:12 September 2012

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

 

* Authors contributed equally to this work.


 

  • References

  • 1 Sirtori CR, Calabresi L, Franceschini G. et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103: 1949-1954.
    CrossrefPubMedGoogle Scholar
  • 2 Ibanez B, Vilahur G, Cimmino G. et al. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 2008; 51: 1104-1109.
    CrossrefPubMedGoogle Scholar
  • 3 Nissen SE, Tsunoda T, Tuzcu EM. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 2003; 290: 2292-2300.
    CrossrefPubMedGoogle Scholar
  • 4 Cimmino G, Ibanez B, Vilahur G. et al. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano). J Cell Mol Med 2009; 13: 3226-3235.
    CrossrefPubMedGoogle Scholar
  • 5 Choi BG, Vilahur G, Cardoso L. et al. Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway. Eur J Clin Invest 2008; 38: 211-217.
    CrossrefPubMedGoogle Scholar
  • 6 Chiesa G, Monteggia E, Marchesi M. et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002; 90: 974-980.
    CrossrefPubMedGoogle Scholar